Department of Physiology, National Taiwan University College of Medicine, Taipei, Taiwan.
Department of Biomedical Sciences, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan.
Neuropharmacology. 2020 Nov 15;179:108266. doi: 10.1016/j.neuropharm.2020.108266. Epub 2020 Aug 24.
Lacosamide is a new-generation anticonvulsant acting on Na channels. Compared to the classic anticonvulsants targeting Na channels, lacosamide is unique in structure and in its molecular action requiring longer membrane depolarization. Selective binding to the slow inactivated state of Na channels was then advocated for lacosamide, although slow binding to the fast inactivated state was alternatively proposed recently. In addition, quantitative characterization of lacosamide action has been deficient. We investigated the interactions between lacosamide and Na channels in native mammalian neurons, and found that the apparent dissociation constant (~13.7 μM) of lacosamide to the slow inactivated state is well within the therapeutic concentration range and is much (>15-fold) lower than the dissociation constant of lacosamide to the fast inactivated state. Besides, lacosamide has extremely slow binding rates (<400 Msec) to the fast but much faster binding rates (>3000 Msec) to the slow inactivated Na channels. Consistent with these biophysical characters, we further demonstrated that lacosamide is much more effective against the repetitive burst discharges with interburst intervals at -60 mV than -80 mV. With preponderant binding to the slow inactivation state in therapeutic concentrations and thus less propensity to affect normal discharges, lacosamide could be a drug of choice for seizure discharges characterized by relatively depolarized interburst intervals, during which more slow inactivated states could be generated and more binding of lacosamide would ensue.
拉科酰胺是一种作用于钠通道的新一代抗惊厥药物。与作用于钠通道的经典抗惊厥药物相比,拉科酰胺在结构和分子作用上具有独特性,需要更长的膜去极化。因此,拉科酰胺被认为选择性结合钠通道的缓慢失活状态,尽管最近也提出了其与快速失活状态的缓慢结合。此外,拉科酰胺作用的定量特征还存在不足。我们研究了拉科酰胺与天然哺乳动物神经元中钠通道的相互作用,发现拉科酰胺与缓慢失活状态的表观解离常数(13.7 μM)在治疗浓度范围内,远低于其与快速失活状态的解离常数(15 倍)。此外,拉科酰胺与快速失活的钠通道的结合速率极慢(<400 Msec),但与缓慢失活的钠通道的结合速率较快(>3000 Msec)。与这些生物物理特性一致,我们进一步证明,拉科酰胺对 -60 mV 而非 -80 mV 处的重复爆发放电的抑制作用要强得多。由于在治疗浓度下优先结合于缓慢失活状态,因此不太可能影响正常放电,拉科酰胺可能是治疗具有相对去极化的爆发间隔的发作性放电的首选药物,在这种情况下,会产生更多的缓慢失活状态,并且会有更多的拉科酰胺结合。